ALNOV Novacyt S.A.
Novacyt S.A., together with its subsidiaries, develops, manufactures, and commercializes a range of molecular assays and instrumentation to deliver workflows and services for human health, animal health, and environmental sectors. It operates through Yourgene Health and Primer Design segments. The Yourgene Health segment delivers molecular diagnostic and screening solutions, across reproductive health and precision medicine. The Primer Design segment designs, manufactures, and markets molecular real-time qPCR testing devices and reagents in the areas of infectious diseases. It operates in the United Kingdom, France, Europe, the United States, the Asia Pacific, the Middle East, and Africa. The company was incorporated in 2006 and is based in Le Vésinet, France.…
Industry Peers
Diagnostics & ResearchKey Statistics
About Novacyt (EPA: ALNOV)
›
Novacyt (EPA: ALNOV) is listed on Euronext Paris, where its shares trade in EUR. It belongs to the Diagnostics & Research industry, part of the Healthcare sector, and reports about 228 employees.
The shares were at 0.4415 EUR on 19 November 2026, up 2.7% over 52 weeks. Its 52-week range is 0.2900 EUR to 1.040 EUR: the price is 57.5% below the high and 52.2% above the low.
Its market capitalisation is 31.89M EUR.
Novacyt reports return on equity of -97.9%, an operating margin of -50.3% and revenue up 18.0% year over year.
Its debt exceeds its cash by 1.32M GBP, a debt-to-equity ratio of 0.45. Its Piotroski F-score is 4 out of 9, an average reading of its financial health.